# Preeclampsia Severe Features

Severe features shift preeclampsia management from outpatient surveillance to maternal stabilization, seizure prophylaxis, blood-pressure control, fetal assessment, and delivery planning. Delivery is indicated after stabilization at 34 weeks or sooner for uncontrolled maternal or fetal deterioration; selected patients before 34 weeks may undergo inpatient expectant management.

**Clinical question:** How should physicians identify severe features of preeclampsia and determine when delivery should occur?

Updated: 2026-09-15T22:23:56.166365+00:00

## What matters in practice
- Classify preeclampsia as having severe features with sustained blood pressure of at least 160/110 mm Hg or specified thrombocytopenic, hepatic, renal, pulmonary, or neurologic involvement; proteinuria is not required. [4][5]
- Treat sustained severe hypertension with a rapid-acting antihypertensive within 30 to 60 minutes and stabilize the mother before delivery. [23][20]
- For preeclampsia with severe features at or beyond 34 weeks, proceed to delivery after maternal stabilization; do not defer indicated delivery solely to complete antenatal corticosteroids. [20][21]
- Before 34 weeks, expectant management is an inpatient option only for carefully selected, initially stable patients with intensive maternal-fetal surveillance and immediate delivery for deterioration. [11][20]
- HELLP syndrome may present without hypertension or proteinuria and requires prompt recognition of hemolysis, elevated liver enzymes, and thrombocytopenia in antepartum or early postpartum patients. [2][3]

## Identify severe features that require delivery-focused management

Use blood pressure plus end-organ findings; do not require proteinuria to recognize severe disease.

After 20 weeks' gestation, diagnose preeclampsia when new hypertension is present on two measurements at least 4 hours apart—systolic blood pressure at least 140 mm Hg or diastolic blood pressure at least 90 mm Hg—with proteinuria or qualifying maternal organ dysfunction. Severe-range blood pressure, defined as systolic at least 160 mm Hg or diastolic at least 110 mm Hg, may be confirmed over minutes rather than 4 hours to permit urgent treatment. [4][5][23]

Preeclampsia with severe features is present with any of the following: platelets below 100,000/mm3; serum creatinine above 1.1 mg/dL or doubling of baseline without another renal explanation; transaminases at least twice the laboratory upper limit of normal; persistent right-upper-quadrant or epigastric pain not explained by another diagnosis; pulmonary edema; or new headache unresponsive to medication without an alternative diagnosis, visual symptoms, or visual disturbance. [4][23][24]

Do not use the amount of proteinuria to downstage a patient with severe blood pressure or end-organ involvement. Establish proteinuria, when needed, with a 24-hour urine protein of at least 300 mg, urine protein-to-creatinine ratio at least 0.3, or dipstick 2+ only if quantitative testing is unavailable. [4][5]
- In chronic hypertension, suspect superimposed preeclampsia after 20 weeks when previously controlled pressure rises or therapy must be escalated, especially with new or abruptly worsened proteinuria or new end-organ dysfunction. [24]
- Treat HELLP syndrome as a severe maternal condition even when hypertension or proteinuria is absent; approximately 15% of affected patients lack classic preeclampsia manifestations. [2][3]
- Consider postpartum preeclampsia through 6 weeks after delivery when severe hypertension or severe features occur without another identifiable cause. [9][23]

*Diagnostic thresholds that change preeclampsia acuity and delivery planning. [4][23][24]*

| Finding | Actionable threshold or presentation | Management implication |
| --- | --- | --- |
| Severe hypertension | SBP at least 160 mm Hg or DBP at least 110 mm Hg; confirm within minutes when sustained. [4][23] | Begin rapid-acting antihypertensive treatment within 30-60 minutes, stabilize, and assess delivery need. [23] |
| Thrombocytopenia | Platelets below 100,000/mm3. [4][24] | Classifies severe features; evaluate for HELLP syndrome and plan delivery based on maternal-fetal status and gestational age. [2][24] |
| Renal involvement | Creatinine above 1.1 mg/dL or doubling from baseline without other renal disease. [4][23] | Classifies severe features and warrants inpatient maternal assessment and delivery planning. [23] |
| Hepatic involvement | AST or ALT at least twice upper limit of normal, or persistent unexplained RUQ/epigastric pain. [4][23][24] | Classifies severe features; assess for HELLP syndrome and expedite delivery if maternal status worsens. [2][20] |
| Pulmonary or neurologic involvement | Pulmonary edema; persistent medication-unresponsive headache; visual symptoms or visual disturbance. [4][23] | Classifies severe features and requires urgent maternal stabilization and delivery-focused management. [20][23] |

## Stabilize severe disease before deciding route and timing of delivery

Maternal stabilization and assessment occur concurrently with fetal evaluation and delivery preparation.

Admit patients with preeclampsia and severe features to labor and delivery or an equivalent inpatient setting for close maternal and fetal surveillance. Obtain a complete blood count, comprehensive metabolic panel, and urine protein-to-creatinine ratio; repeat assessment according to clinical trajectory to detect worsening thrombocytopenia, hepatic injury, or renal dysfunction. [16][23]

For sustained severe hypertension, initiate a rapid-acting antihypertensive within 30 to 60 minutes. The urgent treatment target is prevention of maternal cerebrovascular and other severe complications rather than prolongation of pregnancy; severe hypertension itself may establish postpartum preeclampsia after other causes are excluded. [23]

Use intravenous magnesium sulfate for seizure prophylaxis in preeclampsia with severe features and for treatment or prevention of recurrent seizures in eclampsia. Magnesium sulfate is more effective than placebo, antihypertensives, or phenytoin for prevention of first and recurrent eclamptic seizures. [9][17]
- Assess symptoms that imply end-organ progression at presentation and serially: persistent headache, visual changes, dyspnea, chest findings consistent with pulmonary edema, and persistent RUQ or epigastric pain. [4][23]
- Obtain imaging directed by the presentation rather than routinely; for volume-overload symptoms, consider brain natriuretic peptide, and tailor other imaging to neurologic, cardiopulmonary, or abdominal findings. [23]
- If delivery is likely before 34 weeks and maternal-fetal status permits delay, administer antenatal corticosteroids for fetal benefit; do not postpone indicated delivery to complete the course. [20]

### HELLP syndrome and atypical presentations

Suspect HELLP syndrome in a pregnant or puerperal patient—usually within 7 days of delivery—with microangiopathic hemolysis, elevated liver enzymes, and thrombocytopenia. Hypertension occurs commonly but is not universal; absence of hypertension or proteinuria must not delay evaluation when thrombocytopenia and hepatic abnormalities accompany RUQ pain, nausea, vomiting, headache, or malaise. [2][3]
- A platelet count below 100,000/mm3 and transaminases at least twice normal fulfill severe-feature criteria even before a formal HELLP designation is established. [4][24]
- After initial stabilization, delivery is generally required for severe preeclampsia with HELLP syndrome rather than prolonged expectant management. [20][12]

*Immediate actions for preeclampsia with severe features. [20][23]*

| Priority | Specific action | Result that changes next step |
| --- | --- | --- |
| Blood pressure | Confirm sustained SBP at least 160 mm Hg or DBP at least 110 mm Hg within minutes; use a rapid-acting antihypertensive within 30-60 minutes. [23] | Persistent severe pressure supports urgent delivery-focused management after stabilization. [20][23] |
| Seizure prevention | Administer IV magnesium sulfate for severe features or eclampsia. [9][17] | Seizure or neurologic progression requires immediate obstetric escalation and delivery planning. [20] |
| Laboratory trajectory | Check CBC and comprehensive metabolic panel, including platelets, creatinine, and transaminases. [23] | Platelets below 100,000/mm3, creatinine above 1.1 mg/dL or doubled baseline, or transaminases at least twice normal confirm severe features. [4] |
| Pulmonary and neurologic assessment | Evaluate dyspnea, pulmonary edema, severe headache, and visual symptoms; use presentation-directed imaging. [4][23] | Pulmonary edema or persistent neurologic symptoms is a severe feature requiring expedited maternal-fetal decision-making. [4][20] |
| Fetal preparation | If preterm delivery is anticipated and time permits, give antenatal corticosteroids. [20] | Do not delay indicated delivery solely for steroid completion. [20] |

## Deliver at 34 weeks or later after maternal stabilization

At 34 weeks, maternal benefit from delivery outweighs attempts to prolong pregnancy in severe disease.

Undertake delivery for preeclampsia with severe features at 34 weeks' gestation for patients who remain pregnant to that point, after initial maternal stabilization. This timing applies even when the patient appears temporarily stable because severe disease carries ongoing maternal and fetal risk during continued pregnancy. [20][21]

At gestational ages beyond 37 weeks, planned delivery for gestational hypertension or preeclampsia without severe features reduces adverse maternal outcomes without increasing cesarean delivery or neonatal adverse outcomes in the HYPITAT trial context. This evidence does not support applying outpatient expectant management principles to patients with severe features at or beyond 34 weeks. [10][1][20]

Choose delivery route according to obstetric factors and urgency rather than the diagnosis alone. When maternal or fetal deterioration is present, stabilize immediately and proceed with delivery; cesarean delivery may be necessary when rapid birth is required or vaginal delivery is not feasible. [20][24]
- Severe-feature diagnosis at 34 weeks or later: stabilize severe hypertension, begin magnesium sulfate, assess maternal-fetal status, and initiate delivery. [20][23]
- Do not await normalization of platelets, creatinine, transaminases, headache, pulmonary findings, or blood pressure before delivery when deterioration is ongoing. [20]
- Antenatal corticosteroids can be considered when fetal benefit is feasible, but delivery should not be delayed for their completion when a maternal or fetal indication is present. [20]

*Gestational-age framework for delivery planning in preeclampsia with severe features. [20][21]*

| Gestational age and status | Default management | Exception or escalation |
| --- | --- | --- |
| At or beyond 34 weeks with severe features | Delivery after initial maternal stabilization. [20][21] | Do not defer delivery for corticosteroid completion. [20] |
| Before 34 weeks, initially stable and carefully selected | Consider inpatient expectant management with intensive maternal-fetal surveillance and corticosteroids if time permits. [11][20] | Deliver immediately for maternal or fetal deterioration. [11][20] |
| Any gestational age with uncontrolled maternal or fetal deterioration | Stabilize and proceed to delivery. [20] | Severe hypertension, pulmonary edema, neurologic progression, HELLP-related deterioration, or fetal compromise precludes routine prolongation. [20][23] |

## Use expectant management before 34 weeks only in selected inpatients

The potential neonatal benefit of pregnancy prolongation must be balanced against abrupt maternal or fetal deterioration.

For severe preeclampsia before 34 weeks, expectant management can improve neonatal outcomes in selected patients but requires careful in-hospital maternal and fetal surveillance. It is not a strategy for patients who cannot be stabilized or who develop worsening maternal disease or fetal compromise. [11][20]

Counsel that prolongation is often limited and that delivery indications arise frequently from either fetal or maternal deterioration. In reports of expectant management before 34 weeks, delivery occurred for fetal indications in 46% and maternal indications in 40%; reported complications included placental abruption, pulmonary edema, eclampsia, stroke, stillbirth, and neonatal death. [20]

Do not treat fetal growth restriction as an automatic substitute for a full fetal assessment, but recognize it as a marker of uteroplacental disease that may shorten the safe surveillance interval. Fetal compromise during expectant management is an indication to end pregnancy rather than continue solely to gain gestational age. [11][20]
- Require a setting capable of continuous reassessment and rapid delivery; outpatient expectant management is not appropriate for severe preterm preeclampsia. [11][20]
- Reassess maternal symptoms, severe-range blood pressure, platelet count, creatinine, and liver enzymes for progression during hospitalization. [4][20][23]
- Deliver at 34 weeks if the patient remains pregnant, even after a period of stable expectant management. [20][21]
- In one randomized trial of early severe preeclampsia, expectant management prolonged pregnancy by 8 days but was associated with increased placental abruption (relative risk 5.1; 95% CI, 1.1-23), illustrating the maternal tradeoff of prolongation. [10]

### When not to continue pregnancy

End expectant management for worsening maternal condition or fetal compromise. Maternal triggers include persistent severe hypertension despite acute treatment, pulmonary edema, progressive neurologic symptoms, worsening renal or hepatic dysfunction, thrombocytopenia/HELLP progression, eclampsia, or placental abruption; fetal deterioration also requires delivery. [20][23][24]
- If a trigger develops, do not use corticosteroid completion as a reason to defer delivery. [20]
- Perform maternal stabilization before delivery whenever feasible, including acute treatment of sustained severe hypertension and magnesium sulfate for seizure prophylaxis. [20][23]

*Selection and stop rules for expectant management before 34 weeks. [11][20][23]*

| Domain | Favors a monitored trial of expectant management | Requires delivery-focused escalation |
| --- | --- | --- |
| Maternal status | Initially stable after assessment and stabilization in an inpatient setting. [11][20] | Uncontrolled severe hypertension, pulmonary edema, eclampsia, progressive neurologic symptoms, worsening renal/hepatic dysfunction, HELLP progression, or abruption. [20][23][24] |
| Fetal status | No evidence of fetal compromise during intensive surveillance. [11][20] | Fetal compromise or deterioration. [11][20] |
| Gestational age | Before 34 weeks, when neonatal benefit from prolongation may justify risk in selected cases. [11][20] | 34 weeks reached: deliver after stabilization. [20][21] |
| Care setting | Inpatient maternal-fetal surveillance with capacity for urgent delivery. [11][20] | Inability to provide intensive surveillance or rapid delivery capability. [11][20] |

## Continue surveillance after birth and address recurrence risk

Delivery removes the placenta but does not eliminate immediate postpartum hypertensive or neurologic risk.

Preeclampsia and eclampsia can occur before, during, and up to 6 weeks postpartum. For new postpartum hypertension, confirm nonsevere elevations on two occasions at least 4 hours apart, but confirm severe pressure within minutes and treat sustained blood pressure of at least 160/110 mm Hg with rapid-acting therapy within 30 to 60 minutes. [9][23]

For suspected postpartum preeclampsia, obtain CBC, comprehensive metabolic panel, and urine protein-to-creatinine ratio. In patients with clinical volume overload, consider brain natriuretic peptide; select imaging according to neurologic, cardiopulmonary, or other presenting findings. Severe hypertension alone within 6 weeks postpartum, after other etiologies are excluded, warrants classification and management as postpartum preeclampsia. [23]

At a subsequent pregnancy, prescribe low-dose aspirin 81 mg daily for patients at high risk of preeclampsia, including prior preeclampsia, chronic hypertension, pregestational diabetes, multifetal gestation, or autoimmune disease. For chronic hypertension during pregnancy, treatment targeting blood pressure below 140/90 mm Hg reduced the CHAP trial primary composite outcome without increased fetal growth restriction. [9]
- Document preeclampsia history as a long-term cardiovascular risk marker; survivors have increased later risk of stroke, cardiovascular disease, and diabetes. [8]
- For postpartum headache, visual symptoms, dyspnea, pulmonary edema, or severe hypertension, evaluate urgently rather than attributing symptoms to routine postpartum physiology. [23]
- In chronic hypertension with superimposed severe features, a sudden rise in previously controlled pressure or escalation-resistant severe hypertension plus end-organ dysfunction should trigger severe-disease management. [24]

*Postpartum actions after preeclampsia with severe features. [9][23]*

| Clinical scenario | Immediate assessment | Action |
| --- | --- | --- |
| Severe postpartum hypertension | Confirm SBP at least 160 mm Hg or DBP at least 110 mm Hg within minutes. [23] | Administer rapid-acting antihypertensive therapy within 30-60 minutes and evaluate for postpartum preeclampsia. [23] |
| Postpartum severe-feature symptoms | CBC, comprehensive metabolic panel, urine protein-to-creatinine ratio; presentation-directed imaging. [23] | Manage as postpartum preeclampsia after exclusion of alternative etiologies; use magnesium sulfate for seizure prevention when clinically indicated by severe disease. [9][23] |
| Future pregnancy after prior preeclampsia | Identify high-risk status at prenatal entry. [9] | Use low-dose aspirin 81 mg daily in high-risk patients. [9] |

## Common questions

### Is persistent proteinuria required for preeclampsia with severe features?

No. New hypertension plus thrombocytopenia, renal insufficiency, hepatic dysfunction, pulmonary edema, or persistent cerebral or visual symptoms establishes preeclampsia even without proteinuria; severe-range blood pressure is itself a severe feature. [4][5][23]

### Should corticosteroids delay indicated delivery for severe preeclampsia before 34 weeks?

No. Give antenatal corticosteroids if fetal benefit is feasible, but proceed with delivery after stabilization when maternal or fetal deterioration creates an indication; do not delay solely to complete corticosteroid administration. [20]

## References
1. For Women with Preeclampsia, Immediate Delivery or Expectant Management? | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/women-preeclampsia-immediate-delivery-expectant-management-nejm-jw.NA49859
2. HELLP syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/1000
3. Clinical diagnosis and treatment of “atypical” HELLP syndrome | Gynecology and Obstetrics Clinical Medicine — gocm.bmj.com — https://gocm.bmj.com/content/2/3/105
4. Preeclampsia—Pathophysiology and Clinical Presentations: 
JACC State-of-the-Art Review — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2020.08.014
5. Biomarkers and point of care screening approaches for the management of preeclampsia | Communications Medicine — www.nature.com — https://www.nature.com/articles/s43856-024-00642-4
6. Understanding the role of soluble proteins and exosomes in non-invasive urine-based diagnosis of preeclampsia | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-024-75080-2
7. Development and validation of a prediction model on severe maternal outcomes among pregnant women with pre-eclampsia: a 10-year cohort study | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-020-72527-0
8. Pre-eclampsia | Nature Reviews Disease Primers — www.nature.com — https://www.nature.com/articles/s41572-023-00417-6
9. Cardiometabolic Health in Pregnancy: Prevention, Management, and Long-Term Implications — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacadv.2026.102804
10. Expectant management of severe preeclampsia remote from term: the MEXPRE Latin Study, a randomized, multicenter clinical trial - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002937813008429
11. Expectant management of severe preterm preeclampsia: Is intrauterine growth restriction an indication for immediate delivery? - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0002937800377377
12. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002937807002554
13. Quantifying the additional maternal morbidity in women with preeclampsia with severe features in whom immediate delivery is recommended - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2589933322000052
14. Atypical eclampsia in a normotensive patient with altered mental ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/ijgo.14975
15. Hypertensive Disorders of Pregnancy: Overview and Current ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/jmwh.12725
16. Pregnancy prolongation following diagnosis of pre‐eclampsia with ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.70392
17. Hypertension and pregnancy: expert consensus statement from the ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/fcp.12254
18. Temporizing management vs immediate delivery in early‐onset ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/aogs.13976
19. onset severe preeclampsia between 28 and 34 weeks of gestation ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/pdf/10.1111/aogs.13976
20. pdf — www.ajog.org — https://www.ajog.org/article/S0002-9378(11)00918-5/pdf
21. Evaluation and management of severe preeclampsia before 34 ... — www.ajog.org — https://www.ajog.org/article/s0002-9378(11)00918-5/fulltext
22. Society for Maternal-Fetal Medicine Consult Series #50 — www.ajog.org — https://www.ajog.org/article/S0002-9378(20)30517-2/pdf
23. Postpartum preeclampsia or eclampsia: defining its place and ... — www.ajog.org — https://www.ajog.org/article/S0002-9378(20)31201-1/fulltext
24. Online Exclusive | From the Member Sections | Optimizing Care of Patients with Hypertensive Disorders of Pregnancy: Putting an Enterprise Plan into Action - American College of Cardiology — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2026/03/01/01/online-exclusive-from-the-member-sections-optimizing-care

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.